System and method for billing system interface failover resolution
    51.
    发明授权
    System and method for billing system interface failover resolution 有权
    计费系统接口故障切换解决方案的系统和方法

    公开(公告)号:US08010594B2

    公开(公告)日:2011-08-30

    申请号:US12141203

    申请日:2008-06-18

    Abstract: A determination is made whether a first application server of a group of N application servers, N being at least two, is a coordinator of the group. Responsive to determining that the first application server is the coordinator of the group, a connection to a billing system is established, via a terminal server, by the first application server. A determination is made whether a second application server of the group of N application servers is the coordinator of the group. Responsive to determining that the second application server is not the coordinator of the group, a periodic check is made whether the second application server of the group of N application servers is the coordinator of the group. The second application server may later be determined to be the coordinator of the group, when the first server experiences difficulty. Once it is determined that the second application server now is the coordinator of the group, a connection is established to the billing system, via the terminal server, by the second application server.

    Abstract translation: 确定一组N个应用服务器的第一应用服务器是否为该组的协调器,N至少为两个。 响应于确定第一应用服务器是该组的协调器,通过终端服务器由第一应用服务器建立与计费系统的连接。 确定N个应用服务器组的第二应用服务器是否是该组的协调器。 响应于确定第二应用服务器不是组的协调器,定期检查N个应用服务器组中的第二应用服务器是否是该组的协调器。 当第一服务器遇到困难时,可以将第二应用服务器确定为该组的协调器。 一旦确定第二应用服务器现在是组的协调器,则通过第二应用服务器经由终端服务器向计费系统建立连接。

    Production of isoflavone derivatives
    53.
    发明授权
    Production of isoflavone derivatives 失效
    异黄酮衍生物的生产

    公开(公告)号:US07906660B2

    公开(公告)日:2011-03-15

    申请号:US11442369

    申请日:2006-05-25

    CPC classification number: C07D311/56 C07D311/36 C07D311/38

    Abstract: Methods for the hydrogenation of isoflavones are described which provide access to workable quantities of isoflavan-4-ols, isoflav-3-enes, and isoflavans. The isoflavone derivatives can be obtained in high purity and in near quantitative yields whilst employing pharmaceutically acceptable reagents and solvents.

    Abstract translation: 描述了异黄酮氢化方法,其提供了可使用量的异黄烷-4-醇,异氟烷-3-烯和异构体。 异黄酮衍生物可以以高纯度和接近定量的产率获得,同时使用药学上可接受的试剂和溶剂。

    ACID ADDITION SALTS OF MUSCARINIC RECEPTOR ANTAGONISTS
    55.
    发明申请
    ACID ADDITION SALTS OF MUSCARINIC RECEPTOR ANTAGONISTS 审中-公开
    胃酸受体拮抗剂的酸添加量

    公开(公告)号:US20100035954A1

    公开(公告)日:2010-02-11

    申请号:US11721838

    申请日:2004-12-15

    CPC classification number: C07D209/52

    Abstract: Provided herein are acid addition salts of muscarinic receptor antagonists. Such acid addition salts are muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Also provided herein are processes for the preparation of acid addition salts, pharmaceutical compositions thereof, and methods of treating diseases mediated through muscarinic receptors.

    Abstract translation: 本文提供毒蕈碱受体拮抗剂的酸加成盐。 这种酸加成盐是毒蕈碱受体拮抗剂,其可用于治疗通过毒蕈碱受体介导的呼吸,尿和胃肠道系统的各种疾病。 本文还提供了制备酸加成盐,其药物组合物和治疗通过毒蕈碱受体介导的疾病的方法。

    Synthesis of cyclic compounds
    60.
    发明授权
    Synthesis of cyclic compounds 失效
    环状化合物的合成

    公开(公告)号:US06958145B2

    公开(公告)日:2005-10-25

    申请号:US10312155

    申请日:2001-06-28

    CPC classification number: C07D307/58 C07C59/347 C07D307/60 C08F224/00

    Abstract: A method for the preparation of a compound of formula (II) wherein R1 and R2 are independently H, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more hetero atoms, straight chain or branched chain, hydrophilic, hydrophobic or fluorophilic; R3, R4, R5 and R6 are independently or all hydrogen or halogen; provided that at least two of the R3, R4, R5 and R6 are halogens.

    Abstract translation: 制备式(II)化合物的方法,其中R 1和R 2独立地是H,烷基,烷氧基,氧代烷基,烯基,芳基或芳基烷基,无论是未取代的 或取代的,任选被一个或多个杂原子间隔的直链或支链,亲水的,疏水的或富含荧光的; R 3,R 4,R 5和R 6是独立地或全部是氢或卤素; 条件是R 3,R 4,R 5和R 6中的至少两个是卤素。

Patent Agency Ranking